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Abstract
Background: Rates of labour induction are increasing. We conducted this systematic review to assess the evidence
supporting use of each method of labour induction.
Methods: We listed methods of labour induction then reviewed the evidence supporting each. We searched
MEDLINE and the Cochrane Library between 1980 and November 2010 using multiple terms and combinations,
including labor, induced/or induction of labor, prostaglandin or prostaglandins, misoprostol, Cytotec, 16,16,-
dimethylprostaglandin E2 or E2, dinoprostone; Prepidil, Cervidil, Dinoprost, Carboprost or hemabate; prostin,
oxytocin, misoprostol, membrane sweeping or membrane stripping, amniotomy, balloon catheter or Foley catheter,
hygroscopic dilators, laminaria, dilapan, saline injection, nipple stimulation, intercourse, acupuncture, castor oil,
herbs. We performed a best evidence review of the literature supporting each method. We identified 2048
abstracts and reviewed 283 full text articles. We preferentially included high quality systematic reviews or large
randomised trials. Where no such studies existed, we included the best evidence available from smaller
randomised or quasi-randomised trials.
Results: We included 46 full text articles. We assigned a quality rating to each included article and a strength of
evidence rating to each body of literature. Prostaglandin E2 (PGE2) and vaginal misoprostol were more effective
than oxytocin in bringing about vaginal delivery within 24 hours but were associated with more uterine
hyperstimulation. Mechanical methods reduced uterine hyperstimulation compared with PGE2 and misoprostol, but
increased maternal and neonatal infectious morbidity compared with other methods. Membrane sweeping
reduced post-term gestations. Most included studies were too small to evaluate risk for rare adverse outcomes.
Conclusions: Research is needed to determine benefits and harms of many induction methods.
Background
The incidence of labour induction has increased over
the last decade [1]. Labour induction may be indicated
by medical or obstetrical complications of pregnancy or
may be requested or chosen for non-medical or social
reasons. When a woman and her care provider decide
that labor induction is desired, they must next choose a
method of induction. Several factors may influence the
choice of method for induction of labour including cer-
vical and membrane status, parity, and patient and pro-
vider preference. In this paper we review the evidence
for effectiveness of pharmacologic, mechanical, investi-
gational, and complementary and alternative medicine
means of third trimester labour induction. We also
address possible harms of each method.
We conducted this review to summarize the best evi-
dence available for pregnant women requiring induction
of labor in the third trimester of pregnancy with a live
fetus. We compared each method with placebo and with
other methods of labor induction. The outcomes of this
review were the clinically important benefits and harms
of labor induction specified by the Cochrane Collabora-
tion’s Pregnancy and Childbirth Group in their generic
protocol for induction of labour [2].* Correspondence: mozurk@umich.edu
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Methods
We conducted a comprehensive literature search of the
English language literature using Medline and the
Cochrane Database of Systematic Reviews. The search
covered the period from January 1980 to November
2010. We used combinations of the following search
terms “labor, induced/or induction of labor; prostaglan-
din or prostaglandins, misoprostol; Cytotec; 16,16,-
dimethylprostaglandin E2 or E2; dinoprostone; Prepidil;
Cervidil: Dinoprost; Carboprost or hemabate; prostin,
oxytocin, misoprostol, prostaglandins, membrane sweep-
ing or membrane stripping, amniotomy, balloon catheter
or Foley catheter, hygroscopic dilators, laminaria, dila-
pan, saline injection, nipple stimulation, intercourse,
acupuncture, castor oil, herbs”. Titles and abstracts were
reviewed for possible exclusion by two reviewers (KK or
EM and JC). If both reviewers excluded a citation, we
eliminated that publication from further review. If at
least one reviewer felt the citation might be included or
if there was insufficient information to make a determi-
nation from the title and abstract, we obtained the full
article for review. We identified additional articles for
consideration of inclusion through cross checks of rele-
vant bibliographies. Reference lists were created and
full-text articles were retrieved for further consideration
for inclusion.
In accordance with published guidelines for a “best
evidence” review,[3-5] this study included high-quality
systematic reviews and randomised controlled trials in a
hierarchical fashion. If a high-quality systematic review
was available, only randomised controlled trials (RCT)
published after the search date for the systematic review
were included, except in the instance in which we found
a RCT that had not been identified by the systematic
review’s search or a RCT that had been identified by the
systematic review’s search but which was awaiting classi-
fication. In addition, we included studies with at least
one other comparison group (control, placebo or
another method) for women undergoing induction of
labour at term with a live fetus. We excluded systematic
reviews dealing exclusively with subgroups of partici-
pants, such as nulliparas or women with prelabour rup-
ture of membranes or with only a particular dose or
formulation of the method under study (i.e. low dose or
sustained-release preparations). We excluded dose-ran-
ging studies, comparisons of two different formulations
of the same method and studies in which subjects in
one or more treatment arm received several different
methods of labour induction. We did not exclude stu-
dies in which subjects received oxytocin augmentation
after cervical ripening.
If five or more randomised controlled trials involving
a method of induction were published subsequent to the
search date of the most recent included systematic
review or were “awaiting classification” in the systematic
review, we conducted meta-analyses of the primary out-
comes reported in these studies. Two authors, VR and
UP extracted data independently. Differences were
resolved by a third reviewer (EM) after careful review of
each manuscript. The new data were added to the data
on the comparison available in the Cochrane review.
We computed risk ratios and 95% confidence intervals
for the main outcome measures reported in these subse-
quent studies using Comprehensive Meta-Analysis, Ver-
sion 2, Englewood, NJ. We used the fixed effects
method for these analyses in order to match the mea-
sures of effect reported by the included Cochrane
reviews.
We arranged the methods of labour induction accord-
ing to types including pharmacologic methods, non-
pharmacologic methods, complementary and alternative
medicine methods, and investigational methods. How-
ever, for comparisons of methods with each other, we
followed the pre-specified hierarchy used for the series
of induction of labour Cochrane Reviews and arranged
labour induction methods in that specific order [2]. In
each subsection of this paper, we compare each method
with those methods prior to it on this list. (see Table 1)
All full text articles were independently reviewed by
two authors (EM and KK) for possible inclusion. In
order to be included in this review, trials had to report
on one or more of the outcomes of interest specified by
the Cochrane Collaboration induction of labour generic
protocol [2]. The Cochrane generic protocol identified
the most clinically important benefits and harms of
labor induction as the outcomes of interest. These
included the following five primary outcomes which
were felt to be of most clinical importance: vaginal
delivery not achieved within 24 hours (or period speci-
fied by authors), uterine hyperstimulation with fetal
heart rate (FHR) changes, caesarean section, serious
neonatal morbidity or perinatal death (e.g. seizures,
birth asphyxia defined by trialists, neonatal encephalopa-
thy, disability in childhood), serious maternal morbidity
or death (e.g. uterine rupture, admission to intensive
care unit, septicaemia) [2].
Secondary outcomes included unfavourable or
unchanged cervix after 12 or 24 hours, need for oxyto-
cin augmentation, uterine hyperstimulation without
FHR changes, uterine rupture, epidural analgesia, instru-
mental vaginal delivery, meconium stained amniotic
fluid, Apgar score less than seven at five minutes, neo-
natal intensive care admission, neonatal encephalopathy,
perinatal death, disability in childhood, maternal side
effects including nausea, vomiting and diarrhea. Other
secondary outcomes included postpartum hemorrhage,
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serious maternal complications, maternal infections
including chorioamnionitis and endometritis, and neo-
natal infections including meningitis, pneumonia, and
sepsis. Maternal satisfaction data were included when
available. For each of the methods of induction, we
reported the significant measures of effect (odds ratios
or risk ratios) on our outcomes of interest from the
included systematic reviews and RCTs.
Due to the large number of methods, comparisons
and outcomes, we did not include discussion of sub-
group analyses. However, because of the importance of
cervical status as a determinant of failure of induction
of labor to achieve vaginal birth, we reported on the
effect of induction methods on caesarean deliveries for
the subgroup with unfavorable cervices, where available
in the Cochrane reviews.
Two authors (EM and JC) assigned quality scores to
each included full-text article based on the Scottish
Intercollegiate Guidelines Network (SIGN) quality
assessment instruments. These quality assessment
instruments are designed to assess the internal validity
of each study, and the degree to which the studies’ per-
formance minimized bias [6]. The Scottish Intercollegi-
ate Guidelines Network publishes methodology
checklists for critical appraisal of both randomised con-
trolled trials and for systematic reviews [6].
We systematically reviewed benefits and harms of
each induction method and calculated number needed
to treat (NNT) and number needed to harm (NNH) for
each significant comparison among methods. For com-
parisons including only one trial, we used the “treat as
one trial” method of calculating the NNT [7]. When
more than one trial was included in the comparison, we
calculated NNT from pooled odds ratios and risk ratios
reported in the included meta-analyses using the Visual
Rx, version 2; this method is less prone to bias than the
“treat as one trial” method of NNT calculation [8,9]. For
the purpose of NNT calculations from pooled estimates,
we used risk ratios or odds ratios where reported for
adverse outcomes and odds ratios to calculated NNT
from positive outcomes [9]. When odds ratios were not
available in the source studies, we calculated them from
available data using Comprehensive Meta-Analysis, Ver-
sion 2, Englewood, NJ. NNT estimates were rounded up
to the next whole number whereas NNH estimates were
rounded down to the nearest whole number [7,10].
For each method of induction, two authors (EM and
KK) assigned a level of evidence based on the “GRADE”
(Grading of Recommendations Assessment, Develop-
ment and Evaluation) system [11]. In this system, the
overall strength of evidence is assigned not only based
on study design and conduct, but also on factors such
as the consistency and precision of the results and the
likelihood of publication bias. Overall strength of evi-
dence is classified in the GRADE system as high, inter-
mediate, low or very low. The levels of evidence were
assigned in the following manner. If the preponderance
of evidence supporting a particular method of labor
induction for the outcomes of interest is strong enough
that further research would be unlikely to change the
reviewers’ confidence in the estimate of effect, the evi-
dence quality was assessed as high [11]. If further
research would be likely to have an important impact
on confidence in the estimate, the evidence quality was
assessed as moderate [11]. If further research would be
very likely to have an important impact in the estimate
of effect, the quality of evidence was assessed as low,
and if the estimate of effect is very uncertain, the evi-
dence was assessed as very low [11].
These same authors (EM and KK) also assigned a bal-
ance of benefits and harms and a grade of recommenda-
tion according to GRADE system guidelines [11,12]. For
each clinical intervention under study, the balance of
benefits and harms is assessed, and a grade of recom-
mendation is classified as strong or weak. This systema-
tic review does not have a “stand alone” study protocol.
In reporting outcomes from included study, we followed
PRISMA guidelines [13].
Table 1 Induction of labour methods; hierarchy of
comparisons[2]
(1) placebo/no treatment
(2) vaginal prostaglandin E2
(3) intracervical prostaglandin E2
(4) intravenous oxytocin
(5) amniotomy
(6) intravenous oxytocin with amniotomy
(7) vaginal misoprostol
(8) oral misoprostol
(9) mechanical methods including extra-amniotic Foley catheter
(10) membrane sweeping
(11) extra-amniotic prostaglandins
(12) intravenous prostaglandins
(13) oral prostaglandins, excluding misoprostol
(14) mifepristone
(15) oestrogens with or without amniotomy
(16) corticosteroids
(17) relaxin
(18) hyaluronidase
(19) castor oil, bath, and/or enema
(20) acupuncture
(21) breast stimulation
(22) sexual intercourse
(23) homoeopathic methods
(24) isosorbide mononitrate
(25) buccal or sublingual misoprostol
(26) hypnotic relaxation
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This is a systematic review of previously-published
data and as such does not require ethics approval.
Results
We reviewed 2048 abstracts, of which 283 full text arti-
cles were examined for further consideration for inclu-
sion and from which 46 studies were included. Thus, we
included a total of 46 studies in this systematic review
[14-59]. Included studies are listed in Table 2. The flow
of abstracts and articles through the review process is
outlined in Figure 1. A summary of the overall quality
of evidence and strength of recommendation for each
intervention is presented in Table 3.
Pharmacologic Methods
Intravaginal prostaglandins (PGE2 and PGF2a)
Our search identified one Cochrane systematic review of
vaginal prostaglandin E2 (PGE2) or F2a (PGF2a) [14].
Within this review, 37 studies compared PGE2 with pla-
cebo. Of these, two trials with 384 women addressed
the primary outcome of achieving vaginal delivery
within 24 hours. These studies demonstrated that PGE2
reduced failure to achieve vaginal delivery within 24
hours compared with placebo (36/199 versus 183/185;
Relative Risk [RR] 0.19, 95% Confidence Interval [CI]
0.14 to 0.25; NNT = 2). However, there was significant
between-study heterogeneity in these two included stu-
dies, (P < 0.0001), possibly resulting from differences in
baseline characteristics of included women and differ-
ences in dosing regimens studies [14].
Thirty-four trials with 6399 women compared rates of
caesarean section and demonstrated similar rates
between PGE2 and placebo groups. Fourteen trials
including 1259 women reported that uterine hypersti-
mulation with FHR changes was increased with vaginal
PGE2 compared with placebo (28/642 versus 3/617; RR
4.14, 95% CI 1.93 to 8.90; NNH = 65). Additionally, 13
trials with 3636 women demonstrated that hyperstimu-
lation without FHR changes was also increased (26/1846
versus 7/1790; RR 2.48, 95% CI 1.17 to5.26; NNH =
174). Insufficient data prohibited any conclusions about
serious maternal or neonatal morbidity or death [14].
Three trials with 387 women compared PGF2a with
placebo. PGF2a reduced the need for oxytocin augmen-
tation (2 trials, 122 women, 41/76 versus 41/46; RR
0.65, 95% CI 0.53 to 0.81, NNT = 4). PGF2a reduced
the risk for instrumental vaginal delivery in 2 trials 355
women, 51 of 225 versus 48 of 130, RR 0.60, 95% CI
0.43 to 0.84, NNT = 7) and for epidural analgesia in 3
trials with 387 women (53/241 versus 47 of 146, RR
0.72, 95% CI 0.53 to 0.98, NNT = 17) compared with
placebo. These trials did not demonstrate a difference in
cesarean section rates or any other outcomes of interest
between PGF2a and placebo [14].
Unfavorable cervix subgroup
The authors conducted subgroup analyses of trial parti-
cipants who had cervices unfavorable for induction.
There was no difference in the risk of caesarean delivery
between vaginal PGE2 and placebo in the subgroup of
women with unfavorable cervices (22 trials, 2173
women, 225/1093 versus 254/1080, RR 0.87, 95% CI
0.75 to 1.02) [14].
Summary: Compared with placebo, vaginal PGE2
increases vaginal delivery rates within 24 hours. How-
ever, overall risk of cesarean section was not changed.
PGE2 increases uterine hyperstimulation with FHR
changes.
Cervical PGE2
Our search identified one Cochrane systematic review
of the use of intracervical prostaglandins for cervical
ripening and induction of labour compared with pla-
cebo/no treatment [15]. This Cochrane review
included 28 trials with 3764 women that compared
intracervical PGE2 with placebo/no treatment. Four of
the studies (n = 198) found that use of cervical PGE2
was superior to placebo in decreasing the number of
women who did not achieve vaginal delivery within 24
hours (44/100 versus 71/98; RR 0.61, 95% CI 0.47 to
0.79; NNT = 4). In 27 trials including 3734 women,
there was a non-significant trend toward decreased
risk of caesarean section for women receiving cervical
PGE2 (344/1941 versus 360/1793; RR 0.88; 95% CI
0.77 to 1.01). There were no significant increases in
risk of hyperstimulation with FHR changes. However,
11 trials with 2531 women demonstrated significant
increases in hyperstimulation without FHR changes
(67/1344 versus 37/1187; RR 1.59, 95% CI 1.09 to
2.33; NNH = 55). Serious maternal and neonatal mor-
bidity and mortality were infrequently reported and
available data revealed similar findings in the PGE2
and placebo groups [15].
The authors identified 29 trials including 3881 women
that compared cervical PGE2 with vaginal PGE2. Cervi-
cal PGE2 was less effective than vaginal PGE2 in achiev-
ing vaginal delivery within 24 hours (11 trials, 2200
women, 410/1122 versus 315/1078; RR 1.26; 95% CI
1.12 to1.41; NNH = 14). There was no difference in any
other outcome of interest [15].
Subgroup with unfavorable cervix
Compared with placebo, there was a non-significant
trend toward fewer caesarean sections among women
receiving cervical PGE2 (27 studies, 3716 women, 343/
1931 versus 359/1785, RR 0.88; 95% CI, 0.77 to 1.01). In
26 trials with 3586 women whose cervix were unfavor-
able for induction, there was no difference in caesarean
deliveries between women receiving intracervical and
intravaginal PGE2 [15].
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Table 2 Included Studies
Author Year Indication Study Design SR Final Search Date Study Quality
Kelly[14] 2009 Vaginal Prostaglandins SR, MA May 2009 High
Boulvain[15] 2009 Cervical Prostaglandins SR, MA August 2007 High
Alfirevic[16] 2010 Intravenous oxytocin SR, MA January 2009 High
Kunt[17] 2010 Intravenous oxytocin RCT Medium
Bricker[18] 2009 Amniotomy SR, MA January 2007 High
Howarth[19] 2009 Intravenous oxytocin plus amniotomy SR, MA September 2009 High
Hofmeyr[20] 2010 Vaginal misoprostol SR, MA April 2010 High
Alfirevic[21] 2008 Oral misoprostol SR, MA May 2008 High
Gaffaney[22] 2009 Oral misoprostol RCT High
Nagpal[23] 2009 Oral misoprostol RCT High
Muzonzini[24] 2009 Buccal misoprostol SR, MA December 2003 High
Bartusevicius[25] 2005 Buccal misoprostol SR 2004 High
Souza[26] 2008 Buccal misoprostol SR February 2008 High
Lo[27] 2006 Buccal misoprostol RCT High
Elhassan[28] 2007 Buccal misoprostol RCT High
Boulvain[29] 2010 Mechanical methods SR, MA April 2001 High
Heinemann[30] 2005 Mechanical methods SR, MA November 2005 High
Vaknin[31] 2010 Mechanical methods SR, MA April 2008 High
Moraes Filho[32] 2010 Mechanical methods RCT High
Boulvain[33] 2009 Membrane sweeping SR, MA July 2009 High
Kaul[34] 2004 Membrane sweeping RCT High
Kashanian[35] 2006 Membrane sweeping RCT High
De Miranda[36] 2006 Membrane sweeping RCT High
Hill[37] 2008 Membrane sweeping RCT High
Yildirim[38] 2010 Membrane sweeping RCT High
Hamdan[39] 2009 Membrane sweeping RCT High
Kelly[40] 2009 Castor oil SR, MA August 2009 High
Smith[41] 2009 Acupuncture SR, MA January 2008 High
Selmer-Olsen[45] 2007 Acupuncture RCT High
Smith[42] 2008 Acupuncture RCT High
Asher[43] 2009 Acupuncture RCT High
Modlock[44] 2010 Acupuncture RCT High
Kavanaugh[46] 2009 Breast Stimulation SR, MA September 2009 High
Kavanaugh[47] 2009 Sexual Intercourse SR, MA June 2007 High
Smith[48] 2010 Homeopathic methods SR, MA December 2009 High
Omer[49] 1987 Hypnotic relaxation Quasi-randomised Low
Hutton[50] 2009 Extra-amniotic prostaglandins SR, MA June 2009 High
Luckas[51] 2010 Intravenous prostaglandins SR, MA May 2010 High
French[52] 2009 Oral prostaglandins SR, MA July 2009 High
Hapangama[53] 2009 Mifepristone SR, MA May 2009 High
Thomas[54] 2008 Oestrogen SR, MA January 2008 High
Kavanaugh[55] 2006 Corticosteroids SR, MA December 2005 High
Kelly[56] 2009 Relaxin SR, MA August 2009 High
Kavanaugh[57] 2009 Hyaluronidase SR, MA July 2009 High
Osman[59] 2006 Isosorbide mononitrate RCT High
Habib[58] 2008 Isosorbide mononitrate RCT High
Abbreviations: SR–Systematic Review; MA–Meta-analysis; RCT–Randomised controlled trial
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Summary: Intracervical PGE2 appears more effective
than placebo in achieving vaginal delivery within 24
hours.
Oxytocin
Our search identified one Cochrane systematic review
which included 61 trials with 12,819 women and evalu-
ated oxytocin for induction of labour [16]. Comparisons
were made between intravenous (IV) oxytocin versus
placebo/expectant management (25 trials, 6660 women),
IV oxytocin versus vaginal prostaglandin (PGE2) (27
trials, 4564 women), IV oxytocin versus intracervical
prostaglandins (PGE2) (14 trials, 1331 women), and IV
oxytocin versus vaginal PGF2a (3 trials, 291 women)
[16].
Three trials including 399 women reported that IV
oxytocin, when compared with expectant management,
reduced failure to achieve vaginal delivery within 24
hours (16/191 versus 112/208; RR 0.16, 95% CI 0.10 to
0.25; NNT = 3). Meta-analysis of 24 trials including
6620 women found a small but statistically significant
increased rate of caesarean delivery for women in the
oxytocin group (339/3267 versus 301/3353; RR 1.17,
95% CI 1.01 to1.35; NNH = 66). There was no signifi-
cant difference in uterine hyperstimulation with or with-
out FHR changes. Use of oxytocin significantly reduced
chorioamnionitis (14 studies, 5514 women 144/2720
1765 
Excluded 
283 
Full text 
reviewed 
237 
Excluded 
46 
Included 
Studies 
2048 
Abstracts 
reviewed 
Figure 1 Flow Diagram.
Table 3 Summary: Quality of Evidence and Grades of Recommendation[11,12]
Method Quality of evidence Balance of Benefits/Harms Grade of Recommendation
Vaginal PGE2 Moderate Trade-offs Strong
Cervical PGE2 Moderate Net benefits Strong
Intravenous oxytocin Moderate Trade-offs Strong
Amniotomy Moderate Uncertain trade-offs Weak
Intravenous oxytocin plus Amniotomy Moderate Trade-offs Strong
Vaginal misoprostol Moderate Trade-offs Strong
Oral misoprostol Moderate Trade-offs Strong
Mechanical methods Moderate Trade-offs Weak
Membrane sweeping Moderate Net benefits Strong
Extra-amniotic prostaglandins Moderate No net benefit Strong (against)
Intravenous prostaglandins Moderate Net harms Strong (against)
Oral prostaglandins Moderate Net harms Strong (against)
Mifepristone Moderate Net harms Weak
Oestrogens Very Low Uncertain trade-offs Weak
Corticosteroids Very Low Uncertain trade-offs Weak
Relaxin Moderate Uncertain trade-offs Weak
Hyaluronidase Very low Uncertain trade-offs Weak
Castor oil Very Low Net harms Strong (against)
Acupuncture Moderate No net benefit Weak
Breast stimulation Moderate Uncertain trade-offs Weak
Sexual intercourse Very low Uncertain trade-offs Weak
Homeopathic Methods Very low Uncertain trade-offs Weak
Isosorbide mononitrate Moderate Uncertain trade-offs Weak
Buccal or sublingual misoprostol Moderate Trade-offs Strong
Hypnosis Very low No net benefit Weak
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versus 213/2795; RR 0.69, 95% CI 0.57 to 0.85; NNT =
40); however there was significant heterogeneity among
the included trials for this comparison, (I2 = 65%, P =
0.001) and the authors’ analysis of the studies included
in this comparison using the random effects method
was not statistically significant. Likewise, NICU admis-
sions were reduced by oxytocin compared to placebo or
expectant management, (7 studies, 4387 women, 264/
2196 versus 333/2191; RR 0.79, 95% CI 0.68 to 0.92,
NNT = 32). However, there was significant between
study heterogeneity for this comparison (I2 = 70%, P =
0.0003) and this result was no longer statistically signifi-
cant when the random effects method was used for ana-
lysis. The majority of the studies included in these
comparisons required ruptured membranes for entry,
likely influencing this result. Data were insufficient to
establish conclusions regarding neonatal and maternal
mortality or serious morbidity [16].
Three trials including 260 women reported that oxyto-
cin was associated with more failures to achieve vaginal
delivery within 24 hours than vaginal PGE2 (73/132 ver-
sus 40/128; RR1.77, 95% CI 1.31 to 2.38; NNH = 5).
When comparing oxytocin with vaginal PGE2, there was
no significant difference in the rates of caesarean section
(26 trials, 4514 women, 274/2259 versus 246/2255; RR
1.11, 95% CI 0.94 to 1.30). The incidence of uterine
hyperstimulation with fetal heart rate (FHR) changes
was very low and not different between groups. Fewer
women receiving oxytocin developed chorioamnionitis
than those receiving vaginal PGE2 (4 trials, 2742
women, 54/1381 versus 81/1361; RR 0.66, 95% CI 0.47
to 0.92, NNT = 50). Data were insufficient to draw con-
clusions regarding neonatal and maternal mortality or
morbidity; based on limited data, there were no differ-
ences between groups [16].
Two studies that included 258 women comparing oxy-
tocin with intracervical PGE2 found that oxytocin was
associated with more failure to achieve vaginal deliveries
within 24 hours (63/125 versus 46/133; RR 1.47, 95% CI
1.10 to 1.96; NNH = 7). Oxytocin was associated with
more caesarean deliveries than intracervical PGE2 (14
studies, 1331 women, 123/643 versus 94/688; RR 1.37,
95% CI 1.08 to 1.74; NNH = 20). There was no signifi-
cant difference in uterine hyperstimulation with FHR
changes. There were not enough data to develop con-
clusions regarding neonatal and maternal mortality/mor-
bidity [16].
There were only three trials with 291 women that
compared oxytocin with PGF2a. None reported on the
number of women failing to deliver vaginally within 24
hours. There were no significant differences in uterine
hyperstimulation with FHR changes (one trial 23
women) or rates of caesarean delivery (3 trials 280
women). There were no cases of serious neonatal
morbidity or perinatal deaths in the two studies that
reported this outcome [16].
Unfavorable cervix subgroup
Compared with placebo or expectant management, there
was no difference in caesarean deliveries among partici-
pants with unfavorable cervices (13 trials, 1366 women).
Similarly, there was no difference in caesarean deliveries
among 1041 women in 15 trials with unfavorable cer-
vices who received oxytocin or vaginal PGE2. However,
oxytocin use was more likely to result in caesarean
delivery than intracervical PGE2 (10 trials, 1003 women,
107/477 versus 79/526, RR 1.44, 95% CI, 1.12 to 1.86,
NNH = 16) [16].
Randomised controlled trials published after the search
date of systematic reviews
Our search identified one study including 240 women
that compared oxytocin with vaginal prostaglandin E2
for premature rupture of membranes at term [17]. In
this study, oxytocin was associated with a significantly
shorter time from induction to delivery (3.4 +/- 1.5 ver-
sus 9.6 +/- 4.7 hours; p = 0.02). There was no difference
in the risk of caesarean section [17].
Summary: Oxytocin is more effective than expectant
management or placebo but less effective than vaginal
and cervical PGE2 in bringing about vaginal delivery
within 24 hours. Oxytocin resulted in more caesarean
deliveries than cervical PGE2.
Amniotomy
We identified one Cochrane systematic review of
amniotomy for induction of labour [18]. This review
included two studies with 310 total participants. One
included study compared women receiving amniotomy
with those receiving either oxytocin alone or no inter-
vention. This study was underpowered to detect differ-
ences in any outcome of interest and the review
concluded that no meaningful results could be drawn
from these comparisons. The second included study
compared amniotomy alone to a single dose of vaginal
prostaglandins for women with a favourable cervix and
found a significant increase in the need for oxytocin
augmentation in the amniotomy alone group compared
with the women receiving PGE2 (260 women, 57/130
versus 20/130; RR 2.85, 95% CI 1.82 to4.46; NNH = 3).
There was no difference in caesarean deliveries [18].
Subgroup with unfavorable cervix
There were no studies that included participants with
unfavorable cervices [18].
Summary: Compared with vaginal PGE2, amniotomy
increases the need for oxytocin augmentation.
Oxytocin with amniotomy
Our search identified one Cochrane systematic review
including 17 trials with 2566 women comparing IV
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oxytocin plus amniotomy with other methods for induc-
tion of labour [19]. This review compared amniotomy
plus oxytocin (in varying doses), with placebo, vaginal
prostaglandin E2 or F2a, or amniotomy alone. Oxytocin
plus amniotomy resulted in fewer cases of meconium
stained amniotic fluid than placebo or no treatment
(one trial, 184 participants, 3/92 versus 13/92; RR 0.23,
95% CI 0.07 to 0.78; NNT = 9). There were no other
significant differences in our outcomes of interest for
this comparison [19].
When compared with vaginal prostaglandins, amniot-
omy plus IV oxytocin was associated with more postpar-
tum hemorrhage (2 studies, 160 women, 11/80 versus 2/
80; RR 5.5, CI 1.26 to 24.07; NNH = 9). One RCT of
100 subjects found that more women were dissatisfied
with amniotomy and IV oxytocin than vaginal prosta-
glandins, (26/50 versus 0/50; RR 53, CI 3.32 to 846.51;
NNH = 1). There were no other significant differences
between oxytocin plus amniotomy and vaginal prosta-
glandins [19].
One study with 30 participants compared oxytocin
plus amniotomy with cervical prostaglandins. This study
was too small to detect any differences in outcomes of
interest. Likewise, only two studies with 309 total parti-
cipants compared oxytocin plus amniotomy with oxyto-
cin alone. These studies were also underpowered to
detect differences in any outcome of interest [19].
When compared with those who received amniotomy
alone, fewer women who received amniotomy plus IV
oxytocin were not delivered vaginally at 24 hours (2 stu-
dies, 296 participants, 3/148 versus 24/148; RR 0.13,
95% CI 0.04 to 0.41; NNT = 8). Amniotomy plus IV
oxytocin also resulted in significantly fewer instrumental
vaginal deliveries than amniotomy alone (2 studies, 510
participants, 57/255 versus 88/255; RR 0.65, CI 0.49 to
0.85; NNT = 995% CI 6 to 20) [19].
Unfavorable cervix subgroup
The review included two trials with 106 women who
had cervices unfavorable for induction of labor. There
was no difference in caesarean birth among women allo-
cated to amniotomy and oxytocin versus vaginal prosta-
glandins. There were no other trials including women
with cervices unfavorable for induction [19].
Summary: Oxytocin plus amniotomy is more effective
than amniotomy alone in achieving vaginal delivery
within 24 hours. Oxytocin plus amniotomy may be asso-
ciated with more postpartum hemorrhage and less
maternal satisfaction than vaginal prostaglandins.
Vaginal Misoprostol
The Cochrane review of vaginal misoprostol for labour
induction included 121 trials [20]. There were no signifi-
cant difference in vaginal deliveries not achieved with 24
hours among five trials with 769 women that compared
vaginal misoprostol with placebo/no treatment. Likewise,
in five trials with 777 women, there were no significant
differences in hyperstimulation with FHR changes. Com-
pared with placebo/no treatment, vaginal misoprostol
was associated with more hyperstimulation without FHR
changes (31/313 versus 10/481, 6 trials, 794 women, RR
3.52, 95% CI 1.78 to 6.99, NNH = 19) but with less
meconium stained amniotic fluid (6 trials, 814 partici-
pants, 27/326 versus 83/488, RR 0.56, 95% CI 0.35 to
0.87, NNT = 14) Vaginal misoprostol reduced the num-
ber of participants with a cervix unfavorable or
unchanged after 12 to 24 hours (2 studies 107 women,
4/56 versus 41/51, RR 0.10, 95% CI 0.01 to 0.64, NNT =
2). There was no difference in caesarean deliveries in 10
trials that included 1141 women.
Twenty-two trials with 5,229 participants compared
vaginal misoprostol with other vaginal prostaglandins
for the outcome of vaginal deliveries within 24 hours.
Women receiving misoprostol were less likely to not be
delivered within 24 hours (22 trials 5229 participants,
920/2550 versus 1179/2679, RR 0.77, 95% CI 0.66 to
0.89, NNT = 10) and were less likely to require oxytocin
augmentation (38 trials, 7022 participants, 1355/3465
versus 1794/3557, RR 0.68, 95% CI 0.61 to 0.76, NNT =
7). Meconium-stained amniotic fluid was more common
among subjects receiving misoprostol (18 trials, 3991
women, 246/1909 versus 190/2082, RR 1.35, 95% CI
1.13 to 1.61, NNH = 32). Misoprostol increased uterine
hyperstimulation without FHR changes (26 trials 4804
women 381/2311 versus 199/2493, RR 1.99, 95% CI 1.41
to 2.79, NNH = 13), although hyperstimulation with
FHR changes did not differ (31 trials 5830 women).
Vaginal misoprostol reduced the need for oxytocin aug-
mentation (38 trials, 7022 women, 1355/3465 versus
1794/3557, RR 0.68, 95% CI 0.61 to 0.76, NNT = 7) and
epidural anesthesia (8 trials, 2141 women, 469/1063 ver-
sus 516/1078, RR 0.92 95% CI 0.85 to 0.99, NNH = 27).
Caesarean section rates were not significantly different
[20].
Compared with cervical PGE2, vaginal misoprostol
reduced failure to achieve vaginal delivery within 24
hours (13 trials, 1627 women, 253/814 versus 402/813,
RR 0.63, 95% CI 0.56 to 0.71, NNT = 6). Oxytocin aug-
mentation was required less often with misoprostol
based on 20 trials including 2316 women, (411/1177
versus 727/1139, RR 0.55, 95% CI, 0.48 to 0.64 NNT =
4) and women receiving misoprostol were less likely to
have a cervix unfavorable for induction after 12-24
hours (1 trial, 155 women, 38/76 versus 58/79, RR 0.68,
95% CI 0.52 to0.88, NNT = 5). Women receiving miso-
prostol were less likely to require epidural anesthesia (2
trials, 321 women, 48/160 versus 75/161, RR 0.64, 95%
CI 0.48 to 0.86, NNT = 6). Misoprostol resulted in
more uterine hyperstimulation with FHR changes (20
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trials, 2224 women, 98/1129 versus 39/1095, RR 2.32,
95% CI 1.64 to3.28, NNH = 22) and without FHR
changes (17 trials 2178 women, 194/1097 versus 96/
1081, RR 1.95, 95% CI 1.57 to 2.42, NNH = 12).
Increased rates of meconium-stained amniotic fluid
were observed with use of misoprostol (14 trials 2018
women, 161/1015 versus 123/1003, RR 1.29, 95% CI
1.04 to1.59, NNH = 29). There were no other statisti-
cally significant differences in perinatal or maternal out-
comes [20].
Compared with oxytocin, vaginal misoprostol reduced
the likelihood of participants not being delivered vagin-
ally within 24 hours (10 trials, 1397 women, 135/690
versus 226/707, RR 0.65 95% CI.47 to 0.90, NNT = 9).
Vaginal misoprostol was associated with increased uter-
ine hyperstimulation with FHR changes (9 trials with
1419 women 49/690 versus 28/729, RR 1.87, 95% CI
1.20 to 2.91, NNH = 31) and without FHR changes (15
trials 2050 women, 218/1009 versus 102/1041, RR 2.24,
95% CI 1.82 to 2.77, NNH = 9). Women receiving miso-
prostol were more likely to experience gastrointestinal
side effects than those receiving oxytocin (4 trials 334
women, 15/170 versus 2/164, RR 5.04, 95% CI 1.51 to
16.86, NNH = 21) Caesarean deliveries were less likely
among women receiving vaginal misoprostol (25 trials
3074 women, 258/1527 versus 364/1547, RR 0.76 95%
CI 0.60 to 0.96, NNT = 18) as were instrumental vaginal
deliveries (13 trials, 1639 women, 69/810 versus 96/829,
RR 0.74 95% CI 0.56 to 0.99, NNT = 34). Infants born
to women receiving misoprostol were less likely to have
Apgar score < 7 at 5 minutes of life (13 trials, 1906
women, 22/938 versus 41/968, RR 0.56, 95% CI 0.34 to
0.92, NNT = 54). There were no differences in other
maternal or fetal outcomes of interest [20].
Unfavorable cervix subgroup
Compared with placebo, there was no difference in cae-
sarean deliveries for women receiving vaginal misopros-
tol (7 trials, 862 women). There was no difference in the
likelihood of caesarean deliveries among women receiv-
ing misoprostol or women receiving vaginal PGE2 (28
trials, 5832 women), cervical PGE2 (21 trials, 2499
women) or oxytocin (14 trials, 1598 women) [20].
Summary: Vaginal misoprostol is more likely to result
in vaginal delivery within 24 hours than vaginal or cervi-
cal PGE2 or oxytocin but is associated with increased
uterine hyperstimulation. Compared with IV oxytocin,
vaginal misoprostol may reduce the likelihood of caesar-
ean delivery.
Oral Misoprostol
The Cochrane review of oral misoprostol compared to
other methods of labour induction included 56 RCTs
with a total of 11,590 participants [21]. There were
seven trials with 669 women that compared oral
misoprostol to placebo. Women assigned to receive oral
misoprostol were more likely to give birth vaginally
within 24 hours (1 trial, 96 women, 3/47 versus 20/49;
RR 0.16, CI 0.05 to 0.49; NNT = 3). Oral misoprostol
was also associated with lower caesarean section rates
than placebo (six trials, 629 women, 31/312 versus 51/
317; RR 0.61, 95% CI 0.41 to 0.93; NNT = 16). Fewer
women receiving oral misoprostol required oxytocin
augmentation (6 trials, 535 subjects, 63/266 versus 181/
269; RR 0.35, 95% CI 0.28 to 0.44; NNT = 3) [21].
Ten trials with a total of 3368 women compared oral
misoprostol with vaginal PGE2. Fewer women assigned
to receive oral misoprostol required caesarean delivery
(10 trials, 3368 participants, 340/1599 versus 467/1769;
RR 0.87, 95% CI 0.77 to 0.98; NNT = 30). In two trials
including 930 subjects, more women assigned to oral
misoprostol had an unfavourable cervix after 24 hours
(74/470 versus 51/460; RR 1.41, 95% CI 1.01 to 1.96;
NNH = 22). There were no statistically significant differ-
ences between the groups in any of the other outcomes,
including hyperstimulation with and without FHR
changes and the frequency of meconium-stained amnio-
tic fluid. There was significant heterogeneity (P = 0.002)
among studies comparing oral misoprostol and vaginal
PGE2 for the outcome of uterine hyperstimulation with-
out FHR changes, likely related to the differing doses of
oral misoprostol used in the included studies [21].
Four trials with 681 women compared oral misopros-
tol to intracervical PGE2. Fewer women assigned to oral
misoprostol group failed to deliver vaginally within 24
hours, although this finding was of borderline statistical
significance (2 trials, 391 participants, 81/196 versus
100/195; RR 0.81, 95% CI 0.65–1.00; NNT = 11). Oral
misoprostol was associated with more uterine hypersti-
mulation with FHR changes (3 trials, 490 women, 12/
245 versus 3/245; RR 3.57, 95% CI 1.11 to 11.54; NNH
= 32). There was a trend of borderline significance
toward more hyperstimulation without FHR changes
with oral misoprostol (1 trial, 190 women, 8/95 versus
0/95; RR 17.01, 95% CI 1.00 to 290.42). There were no
differences in any other outcome of interest [21].
Eight trials including 1026 women compared oral mis-
oprostol with IV oxytocin. Meconium staining of the
amniotic fluid was seen more frequently in the miso-
prostol group (6 trials, 916 women, 47/477 versus 24/
439; RR 1.72, 95% CI 1.08 to 2.74; NNH = 26), but oral
misoprostol was not associated with any other differ-
ences in adverse fetal, neonatal or maternal outcomes
[21].
Twenty-six trials with 5096 participants compared oral
with vaginal misoprostol. The oral route of administra-
tion was associated with more frequent use of oxytocin
(22 trials, 4557 women, 1301/2279 versus 1151/2278;
RR 1.19, 95% CI 1.06 to 1.34; NNH = 11), but there was
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no difference in vaginal delivery within 24 hours. There
were significantly lower rates of uterine hyperstimula-
tion without FHR changes with oral regimens (9 trials,
1420 women, 85/698 versus 146/722; RR 0.58, 95% CI
0.35 to 0.96; NNT = 12), but the rate of hyperstimula-
tion with FHR changes was not different between the
two groups. Fewer babies born to mothers who received
oral misoprostol had Apgar scores less than 7 at five
minutes of life (14 trials, 3270 women 37/1638 versus
57/1632; RR 0.65, 95% CI 0.44 to 0.97; NNT = 82).
There was no difference in caesarean deliveries in 25
trials with 5096 women [21].
Unfavorable cervix subgroup
There were no studies comparing oral misoprostol with
placebo, vaginal PGE2, intracervical PGE2, or oxytocin
that reported on caesarean deliveries among women
with unfavorable cervices. Among women with unfavor-
able cervices who were randomized to receive oral miso-
prostol or vaginal misoprostol there were no differences
in caesarean deliveries among primiparous (2 studies, 85
participants) or multiparous (1 study, 24 participants)
subjects [21].
Randomised controlled trials published after the search
date of systematic reviews
Subsequent to the search date of the Cochrane review,
we identified one study with 87 participants that com-
pared oral misoprostol with placebo [22]. This study
found oral misoprostol superior to placebo in achieving
delivery within 24 hours (19/43 versus 6/44, P = 0.024,
NNT = 4). An additional study that compared oral mis-
oprostol with PGE2 found that more women receiving
misoprostol delivered vaginally within 12 hours,
although vaginal deliveries within 24 hours did not differ
[23]. More women receiving oral misoprostol were satis-
fied with their induction method [23].
Summary: Oral misoprostol reduced caesarean sections
compared with vaginal PGE2 and placebo. Compared
with vaginal misoprostol, oral misoprostol is associated
with fewer contractile abnormalities, but more need for
oxytocin augmentation.
Buccal or sublingual misoprostol
Our search uncovered three systematic reviews compar-
ing sublingual or buccal misoprostol with other methods
of labour induction [24-26]. The Cochrane review by
Muzonzini[24] and colleagues and the review by Bartu-
sevicius and colleagues[25] both included the same
three studies with a total of 507 women and reached
similar conclusions. Two of the studies with a total of
350 women compared buccal or sublingual misoprostol
(50 μg) to oral misoprostol (50 or 100 μg) and one
study with 157 participants compared buccal and vaginal
misoprostol. Neither review found significant differences
in any outcome of interest [24,25].
Unfavorable cervix subgroup
The Cochrane reviewers did not conduct any subgroup
analyses according to cervical status [24].
Other systematic reviews
In 2008 Souza and colleagues published a systematic
review of studies comparing sublingual or buccal miso-
prostol with vaginal misoprostol for induction of labour.
This review included five studies with 740 subjects [26].
The authors found no significant differences in the rates
of vaginal delivery not achieved within 24 hours, hyper-
stimulation, or cesarean deliveries. There were more
cases of uterine tachysystole, defined as more than five
contractions in 10 minutes for at least 20 minutes,
among women assigned to sublingual misoprostol (5
trials, 740 women, 42/368 versus 26/372; OR 1.70, 95%
CI 1.02 to 2.83; NNH = 24, 95% CI 10 to 771), although
there was significant heterogeneity among studies
included in this comparison (P = 0.04) [26].
Randomised controlled trials published after the search
date of systematic reviews
Our search identified two additional studies carried out
subsequent to the search dates of these systematic
reviews. One of these studies compared sublingual miso-
prostol 50 μg with amniotomy and oxytocin for induc-
tion of labour among 50 women at term with favourable
cervices [27]. This study was terminated early when an
interim analysis revealed that significantly fewer women
allocated to sublingual misoprostol delivered within 24
hours (15/22 versus21/21; RR 0.68, 95% CI 0.51 to 0.91;
NNH = 3). There were no differences in other maternal
or fetal outcomes, although maternal satisfaction was
significantly higher with sublingual misoprostol. The
second study included 150 women and compared 50 μg
misoprosol by oral, vaginal, or sublingual routes [28].
This study found that the induction to delivery interval
was significantly decreased among women receiving sub-
lingual misoprostol compared with the vaginal and oral
routes (13.3 hours versus 16.1 hours [oral] versus 15.1
hours [vaginal]). Fewer babies born to mothers receiving
sublingual misoprostol had Apgar scores less than seven
at one minute (0/50 versus 6/100, P = 0.003, NNT =
17) [28].
Summary: Compared with vaginal misoprostol, admin-
istration of misoprostol by the buccal or sublingual route
increases uterine tachysystole.
Mechanical methods
Our search identified three systematic reviews evaluat-
ing mechanical methods for induction of labour. The
Cochrane review studied mechanical methods includ-
ing laminaria tents, synthetic equivalents such as Dila-
pan, Foley catheters, and other types of balloon
catheter for induction of labour. It included 45 RCTs
that compared mechanical methods with PGE2,
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misoprostol, oxytocin, and placebo. Most trials had
small sample sizes [29].
The authors did not find any advantage of mechanical
methods compared with placebo or no treatment in the
pre-specified outcomes of vaginal delivery not achieved
within 24 hours or caesarean deliveries (1 trial, 48
women). There was no difference in caesarean deliveries
between women receiving mechanical methods and
women receiving placebo or no treatment (6 studies,
416 participants). There was no difference in any other
outcome of interest, including chorioamnionitis (1 trial,
240 participants) and endometritis (2 trials, 288 partici-
pants) [29].
More subjects allocated to mechanical methods failed
to deliver vaginally within 24 hours than those assigned
to vaginal PGE2 (1 trial, 109 participants, 43/59 versus
21/50, RR 1.74, CI 1.21 to 2.49; NNH = 3), and more
women allocated to mechanical methods required oxy-
tocin augmentation (2 trials, 169 women, 30/89 versus
9/80, RR 2.90, 95% CI 1.40 to 6.00, NNH = 5), although
this finding should be interpreted with caution, as there
was significant heterogeneity between the 2 studies
included in this comparison (P = 0.0008). Mechanical
methods were less likely to result in uterine hyperstimu-
lation with FHR changes in 6 trials with 484 women, (0/
246 versus 14/238, RR 0.14, 95% CI 0.04 to 0.53, NNT
= 20) and without FHR changes in 8 trials with 580
women (6/293 vs 28/287, RR 0.26, 95% CI 0.13 to 0.54,
NNT = 14). There was no difference in caesarean deliv-
eries between mechanical methods and vaginal PGE2
(12 trials, 786 women), but mechanical methods were
associated with reduced need for instrumental vaginal
deliveries (5 trials, 378 women, 36/192 versus 53/186,
RR 0.65, 95% CI 0.46 to 0.93, NNT = 11) [29].
More women assigned to mechanical methods did not
achieve vaginal delivery within 24 hours than those
assigned to cervical PGE2 (1 trial, 100 participants, 34/
50 versus 20/50; RR 1.70, CI 1.15 to 2.50; NNH = 3),
and more women allocated to mechanical methods
required oxytocin augmentation (1 trial, 185 women,
84/90 versus 63/95, RR 1.41, 95% CI 1.21 to 1.64, NNH
= 3). However, there was no difference in caesarean sec-
tions in 12 trials that included 1614 women. Compared
with cervical PGE2, mechanical methods were associated
with less endometritis (4 trials, 693 participants, 9/352
versus 34/341 RR 0.26, 95% CI 0.13 to 0.52, NNT = 14).
However, in 3 studies with 619 women that compared
mechanical methods to cervical PGE2, there were more
neonatal infections in babies born to mothers who had
received mechanical methods compared to cervical
PGE2 (24/316 versus 9/303, RR 2.45 95% CI 1.18, to
5.07, NNH = 24) [29].
Analysis of four studies with 198 women comparing
mechanical methods with oxytocin found that
mechanical methods resulted in fewer caesarean deliv-
eries (18/103 versus 30/95; RR 0.55, 95% CI 0.33 to
0.91; NNT = 8). There was no difference in hyperstimu-
lation without FHR changes, postpartum hemorrhage, or
serious maternal morbidity or death in 1 trial with 60
women. No other outcomes could be evaluated for this
comparison [29].
Four studies including 618 women compared mechan-
ical methods to vaginal misoprostol. There were no sta-
tistical differences in the likelihood of achieving vaginal
delivery within 24 hours (2 studies, 234 women) or in
caesarean deliveries (4 studies, 618 women). There was
reduced risk for uterine hyperstimulation with FHR
changes seen in three trials including 434 women com-
paring mechanical methods to vaginal misoprostol (8/
226 versus 19/208; RR 0.41, CI 0.20 to 0.87; NNT = 19).
There were no differences noted in infectious morbidity
or neonatal outcomes [29].
Unfavorable cervix subgroup
There was no difference in caesarean deliveries among
396 women enrolled in five randomized controlled trials
comparing mechanical methods with placebo or no
treatment, in 10 trials with 738 women comparing
mechanical methods with vaginal PGE2 or in 12 trials
with 1614 women comparing mechanical methods with
intracervical PGE2. There was no difference in cesarean
sections in three trials with 482 participants comparing
mechanical methods with vaginal misoprostol. In the
subgroup of women with unfavorable cervices, mechani-
cal methods were less likely to result in caesarean deliv-
ery than oxytocin (3 trials, 178 women, 15/93 versus 27/
85, RR 0.50, 95% CI, 0.29 to 0.87, NNT = 7) [29].
Other systematic reviews
Our search identified a second systematic review that
compared mechanical methods of labour induction with
PGE2, misoprostol, hyaluronidase or placebo [30]. This
systematic review, which included 30 randomised, con-
trolled trials with a total of 4468 participants, focused
on the outcomes of maternal and neonatal infectious
morbidity. The authors defined maternal infectious mor-
bidity as maternal temperature greater than 38°C, endo-
metritis or chorioamnionitis. They defined neonatal
infectious morbidity as fever, suspected or proven sepsis,
or need for antibiotics. Controls were the pooled group
of women who had received other pharmacologic meth-
ods of labour induction. Compared with controls,
women undergoing labour induction with mechanical
methods were more likely to experience infectious mor-
bidity (30 studies, 4468 participants, 252/2220 versus
188/2248; OR 1.38, 95% CI 1.12 to 1.68; NNH = 36).
The authors reported no significant heterogeneity for
this comparison. Similarly, infants born to mothers
undergoing mechanical methods of induction were
more likely to experience neonatal infectious morbidity
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than infants born to mothers undergoing induction with
pharmacologic methods (8 trials, 1775 women, 40/893
versus 18/882; OR 2.03, 95% CI 1.19 to 3.51; NNH =
50). The authors reported that there was no significant
heterogeneity for this comparison [30].
A third systematic review compared mechanical meth-
ods (Foley catheter balloon) with locally applied prosta-
glandins (vaginal PGE2, cervical PGE2 and vaginal
misoprostol) [31]. This systematic review included 27
randomized controlled trials that included 3532 partici-
pants. When compared with all locally applied prosta-
glandins (LAPG) combined, there were no differences
between mechanical methods and prostaglandins in cae-
sarean deliveries (27 trial, 3532 participants), partici-
pants with cervices that were unfavorable or unchanged
after 12 to 24 hours (6 trials, 613 participants), ripening
to delivery interval (13 trials, 1270 participants), vaginal
deliveries within 12 to 24 hours (13 trials, 1779 women),
maternal fevers (19 trials, 2421 women), 5-minute
Apgar scores less than 7 (14 trials, 1661 women), meco-
nium staining (13 trials 1841 women), or admission of
the neonate to a NICU (12 trials, 1796 women). Women
who received LAPG were less likely to require oxytocin
augmentation than those receiving mechanical methods
(16 trials, 1644 participants, RR 0.73, 95% CI 0.62 to
0.86, P = 0.0002), but were more likely to experience
excessive uterine activity, defined as tachysystole, hyper-
tonus, or hyperstimulation syndrome (21 trials, 2661
participants, 244/1306 versus 147/1355, RR, 2.35; 95%
CI, 1.41 to 3.90; P = .001, NNH for locally applied pros-
taglandins when compared with mechanical methods =
7). There was significant heterogeneity noted for the
outcomes of excessive uterine activity, vaginal delivery
within 12-24 hours, and for need for oxytocin augmen-
tation [31].
The authors conducted subgroup analyses comparing
mechanical methods with vaginal PGE2, cervical PGE2,
and vaginal misoprostol. They found that mechanical
methods were associated with a longer ripening to deliv-
ery interval than cervical PGE2 (5 trials, 552 subjects,
weighted mean difference [WMD] 5.48 hours, 95% CI
2.79 to 8.16, P < 0.0001) and vaginal PGE2 (2 trials, 118
subjects, WMD,4.55 hours, 95% CI, 0.33 to 8.77; P =
.03). Cervical PGE2 was associated with a higher risk for
caesarean deliveries than mechanical methods in seven
trials with 896 women (OR 1.27, 95% CI 1.01 to 1.59, P
= 0.04). Vaginal misoprostol was associated with
increased risk for excessive uterine activity compared
with Foley balloon in 13 trials with 1847 participants,
RR 3.41, 95% CI, 1.97 to 5.90; P = 0.0001) [31].
Randomised controlled trials published after the search
date of systematic reviews
We included one additional trial that was published sub-
sequent to the search date of the third systematic review
[32]. This trial randomly assigned 240 women to receive
vaginal misoprostol 25 μg or a Foley catheter for labor
induction. This study found that the Foley catheter was
associated with a longer induction to vaginal delivery
interval than the vaginal misoprostol (20.2 hours versus
17.3 hours, P = 0.016). There were no significant differ-
ences in other outcomes of interest [32].
Summary: Mechanical methods are less likely to result
in uterine hyperstimulation than PGE2 or vaginal miso-
prostol, but may be associated with increased maternal
and neonatal infectious morbidity.
Membrane Sweeping
Our search identified one Cochrane systematic review of
22 trials which included 2797 subjects that compared
membrane sweeping with oxytocin, PGE2, or no treat-
ment [33]. There was no difference in rates of caesarean
deliveries, serious neonatal morbidity, perinatal death,
serious maternal or neonatal infections when comparing
membrane sweeping with no treatment. A policy of rou-
tine membrane sweeping from 37 weeks onward
reduced the likelihood of gestation continuing to both
41 (6 studies, 937 women, 77/473 versus 129/464; RR
0.59, 95% CI 0.46 to 0.74; NNT = 9) and 42 (6 studies,
722 women, 12/365 versus 43/357; RR 0.28, 95% CI 0.15
to 0.50; NNT = 12) weeks’ gestation. Membrane sweep-
ing was associated with reduced likelihood of not being
in labour within 48 hours (five studies, 726 women,
234/367 versus 298/359; RR 0.77, 95% CI 0.70 to 0.84;
NNT = 6). Membrane sweeping was also associated
with reduced risk for not being delivered within one
week (9 studies, 1375 women, 320/695 versus 440/680;
RR 0.71, 95% CI 0.65 to 0.78; NNT = 6). Membrane
sweeping was associated with more vaginal bleeding (3
trials, 391 women, 35/200 versus 18/191; RR 1.75, 95%
CI 1.08 to 2.83; NNH = 15) and more maternal discom-
fort (2 studies, 320 women, 94/163 versus 32/157; RR
2.83, 95% CI 2.03 to 3.96; NNH = 3) compared with no
treatment. Data comparing membrane sweeping with
PGE2 and with oxytocin were insufficient to draw con-
clusions of relative efficacy [33].
Unfavorable cervix subgroup
There was no difference in caesarean sections among
women allocated to membrane sweeping versus no
treatment (3 trials, 200 women) nor in two trials with
252 women comparing membrane sweeping with vaginal
prostaglandins nor in one trial with 69 women compar-
ing membrane sweeping with oxytocin [33].
Randomised controlled trials published after the search
date of systematic reviews or awaiting classification
Among the studies awaiting classification in the
Cochrane review were five high quality RCTs [34-38]. In
addition, we identified one additional high quality RCT
that was published after the Cochrane review’s search
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date [39]. Of these, five studies with 1700 participants
compared membrane sweeping with no treatment or
vaginal exam alone [35-39]. In a meta-analysis that
added our independently-extracted data from the two
studies [36,37] that evaluating the effect of membrane
sweeping on post-term gestations to the data reported
in the Cochrane review, membrane sweeping signifi-
cantly decreased the number of pregnancies progressing
to 42 weeks’ gestation (8 studies, 1874 participants, 102/
902 versus 194/862, RR 0.53, 95% CI 0.43 to 0.65, NNT
= 10). There was no significant heterogeneity for this
comparison. Thus the addition of these two new trials
did not alter the conclusion reached by the Cochrane
review.
DeMiranda found that membrane sweeping significantly
reduced the time from randomization to delivery by one
day (3.50 versus 4.47 days, mean difference 0.97 days; 95%
CI 0.60 to 1.35) [36]. In a more recent study involving 351
women, Yildirim and colleagues found that membrane
sweeping significantly increased the likelihood of sponta-
neous labor by 41 weeks’ gestation (162/179 versus 118/
167, P = 0.0001) [38]. By contrast, Hamdan found that
membrane sweeping did not increase the proportion of
women planning trial of labor after prior cesarean section
(TOLAC) who entered spontaneous labor [39]. The Hill
study was designed to test whether membrane sweeping
increases prelabour rupture of membranes, but found no
overall difference in this outcome [37]. One study with 60
participants compared membrane sweeping with a single
dose of intracervical PGE2 [34]. Use of cervical PGE2
resulted in a significantly shorter intervention to delivery
interval than did membrane sweeping (26.23 hours versus
19.15 hours, P < 0.01) [34].
Summary: Membrane sweeping reduces the risk of
post-term gestation.
Complementary and Alternative Medicine
Methods
Castor Oil
Our search identified one systematic review of the effi-
cacy of castor oil for induction of labour [40]. The
authors of this Cochrane review identified only one
study with 100 subjects comparing castor oil with no
treatment. The trial was judged to be of poor methodo-
logic quality due to methods of allocation. There were
no observed differences in rates of caesarean delivery,
meconium stained fluid, or Apgar less than 7 at five
minutes. More women receiving castor oil reported
experiencing nausea (52/52 versus 0/48; RR 97.08, 95%
CI 6.16 to 150.34; NNH = 1) [40].
Unfavorable cervix subgroup
In one trial with 100 women, there was no difference in
caesarean deliveries between women who received cas-
tor oil or no treatment [40].
Summary: Compared with no treatment, castor oil is
associated with increased maternal side effects.
Acupuncture
Our search identified a Cochrane systematic review that
included 3 trials with 212 women that focused on acu-
puncture for induction of labour [41]. Compared with
standard care (oxytocin, prostaglandins, or “routine
care”), more women undergoing acupuncture did not
require the use of other induction methods (2 trials, 147
women, 49/73 versus 34/74; RR 1.45, 95% CI 1.08
to1.95; NNT = 5). No differences were found in time to
delivery, rates of caesarean delivery, instrumental vaginal
delivery, or epidural anesthesia. Fetal or neonatal out-
comes were not estimable [41].
Unfavorable cervix subgroup
There was no data in the included trials concerning the
effect of acupuncture for labor induction in women with
unfavorable cervices [41].
Randomised controlled trials published after the search
date of systematic reviews
We identified three further trials with 684 participants,
three published after the search date of the systematic
review [42-44] and one that was not identified by the
Cochrane search [45]. These studies did not reveal any
differences between acupuncture and placebo or no
treatment in any outcome of interest.
Summary: The use of acupuncture for induction of
labour is investigational; no advantages for this method
have been demonstrated.
Breast Stimulation
Our search identified one systematic review that com-
bined six studies with 719 subjects that evaluated breast
stimulation for labour induction [46]. There were no
differences in cesarean deliveries, meconium staining, or
uterine hyperstimulation when comparing breast stimu-
lation with no treatment. Breast stimulation decreased
the number of women who were not in labour within
72 hours (4 studies, 437 women, 136/217 versus 206/
220; RR 0.67, 95% CI 0.60 to 0.74; NNT = 4). Breast sti-
mulation was associated with less postpartum hemor-
rhage (2 studies, 300 women, 1/150 versus 9/150; RR
0.16, 95% CI 0.03 to 0.87; NNT = 20). There were more
perinatal deaths among pregnancies assigned to breast
stimulation than to no treatment, although this differ-
ence was not statistically significant (3 studies, 337 par-
ticipants, 3/167 versus 0/170; RR 8.17, 95% CI 0.45 to
147.8). This result should be interpreted with caution, as
all of the deaths occurred in a single trial conducted
among high risk women in a developing country [46].
Two studies with a total of 99 subjects compared
breast stimulation with oxytocin. There were no differ-
ences in caesarean deliveries. In one trial with 37
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women, more women assigned to breast stimulation
were not in labour within 72 hours compared with
those who were allocated to the oxytocin group,
although this difference was of borderline statistical sig-
nificance (10/17 versus 5/20; RR 2.35, 95% CI 1.00 to
5.54). There were no differences in uterine hyperstimu-
lation or meconium staining. There were three perinatal
deaths in the breast stimulation group versus one in the
oxytocin group, a non-significant difference. All deaths
were from the same trial conducted among high risk
women in a developing-world setting [46].
Unfavorable cervix subgroup
There was no information on cesarean deliveries in the
one included trial that included women with unfavor-
able cervices [46].
Summary: Breast stimulation may reduce the number
of women not in labour within 72 hours compared to no
treatment but is less effective than oxytocin for this out-
come. More research is needed to evaluate the safety of
breast stimulation.
Intercourse
The Cochrane review of intercourse for induction of
labour included one study with 28 subjects [47]. Partici-
pants were assigned to have intercourse nightly for
three nights versus no intercourse. There were no differ-
ences in delivery within three days or five minute Apgar
less than seven [47].
Unfavorable cervix subgroup
There was no information on cervical status or cesarean
deliveries in the one included study [47].
Summary: There is not enough evidence to evaluate the
efficacy and safety of intercourse for induction of labour.
Homeopathic methods
Our search identified one systematic review of two stu-
dies with 133 participants that compared homeopathic
herbs for labour induction with placebo [48]. Only one
of the studies included in the Cochrane review reported
on the pre-specified clinical outcomes of interest. That
study included 40 subjects and reported no difference in
rates of vaginal delivery not achieved with 24 hours, cae-
sarean deliveries, operative vaginal delivery, need for
oxytocin augmentation of labour, or length of labour
[48].
Unfavorable cervix subgroup
There was no information in the included study on cer-
vical status [48].
Summary: There is not enough evidence to evaluate the
risks and benefits of homeopathy for induction of labour.
Hypnotic Relaxation
We identified one quasi-randomised study of hypnotic
relaxation for induction of labour in post-term
pregnancies [49]. Forty women were assigned to hypno-
tic relaxation and an equal number to no intervention
based on alternate days of the week. Controls were also
chosen based on the baseline characteristics of parity,
gestational age, and cervical status. There were no dif-
ferences in delivery within 24 hours or time to delivery.
The authors did not report any other outcomes [49].
Unfavorable cervix subgroup
There was no information on the effect of hypnotic
relaxation among women with unfavorable cervices [49].
Summary: Compared to no intervention, hypnotic
relaxation did not affect likelihood of delivery within 24
hours. Data were insufficient to evaluate any other
outcome.
Investigational Methods
Extra-amniotic prostaglandins
Extra-amniotic placement of prostaglandins has been stu-
died as a combination of a mechanical method (Foley
catheter) with a pharmacologic method (prostaglandins)
[50]. The prostaglandin is introduced into the extra-
amniotic space via the catheter. Our search identified
one systematic review comparing extra-amniotic prosta-
glandins with other methods for induction of labour.
This review included 12 studies which compared extra-
amniotic PGE2 or PGF2a with extra-amniotic placebo,
vaginal prostaglandins, intracervical prostaglandins, IV
oxytocin, vaginal misoprostol, or mechanical methods.
Because of the wide variety of comparisons, with fewer
than 200 participants in each of the individual compari-
sons, evaluation of this modality compared to other
methods was limited. Three RCTs with 167 women com-
pared extra-amniotic prostaglandins with placebo.
Women receiving extra-amniotic prostaglandins were
less likely to require oxytocin augmentation (34/84 versus
66/83; RR 0.51, 95% CI 0.39 to 0.67; NNT = 3). Extra-
amniotic PGE2 reduced the likelihood of cervix unfa-
vourable for induction after 12 to 24 hours compared
with Foley catheter alone (1 trial, 187 participants, 27/90
versus 49/97; RR 0.59, 95% CI 0.41–0.86; NNT = 5) [50].
The authors found that women allocated to extra-
amniotic F2a prostaglandins were more likely to be not
vaginally delivered within 24 hours than women receiv-
ing vaginal misoprostol (1 trial, 152 women, 34/76 ver-
sus 14/76, RR 2.43; 95% CI 1.42 to 4.15; NNH = 3).
Women were more likely to be satisfied with extra-
amniotic prostaglandins compared with vaginal PGE2 (1
trial, 62 women, mean difference 4.40, 95% CI 3.50 to
5.30). Evaluation of other maternal and fetal outcomes
was limited due to the small numbers of included
women and many different types of comparison [50].
Unfavorable cervix subgroup
There was no difference in caesarean deliveries among
women receiving extra-amniotic PGE2 versus extra-
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amniotic placebo (2 trials, 60 participants) nor between
women receiving extra-amniotic PGF2a and extra-
amniotic placebo (1 trial, 25 participants). There was no
difference in caesarean sections between women receiv-
ing extra-amniotic PGE2 and vaginal PGE2 (3 trials with
142 women), or between women receiving extra-amnio-
tic PGE2 and intracervical PGE2 (1 trial 194 women).
One trial with 30 participants with unfavorable cervices
found no difference in caesarean deliveries between
women receiving extra-amniotic PGE2 and oxytocin. In
one trial with 77 women there was no difference in cae-
sarean sections between women receiving an intracervi-
cal Foley catheter and extra-amniotic PGE2. There was
no data for comparison of vaginal or oral misoprostol
with extra-amniotic PGE2 among women with unfavor-
able cervices [50].
Summary: Data are insufficient to recommend extra-
amniotic prostaglandins.
Intravenous prostaglandins
In the 1970s and 1980s, IV prostaglandins were investi-
gated as a potential option for induction of labour [51].
Our search identified one systematic review comparing
IV prostaglandins (PGE2 or IV PGF2a) with oxytocin.
This Cochrane review included thirteen trials, with a
total of 1165 women, which were carried out between
1970 and 1987. Compared with IV oxytocin, the use of
IV prostaglandin was associated with higher rates of
uterine hyperstimulation both with FHR changes (5
trials, 390 women, 9/199 versus 0/191; RR 6.76, 95% CI
1.23 to 37.11, NNH = not estimable) and without FHR
changes (5 trials 318 women, 17/159 versus 4/159; RR
4.25, 95% CI 1.48 to 12.24, NNH = 13). However, there
was no difference in caesarean deliveries. Maternal side
effects, defined as gastrointestinal symptoms, fever, and
thrombophlebitis were more common in the IV prosta-
glandin group (8 trials, 940 women, 87/474 versus 22/
466; RR 3.75, 95% CI 2.46 to 5.70, NNH = 8). There
were four perinatal deaths among 491 women who
received IV prostaglandins compared to no perinatal
deaths among 483 women who received IV oxytocin.
This difference was not statistically significant. There
were no differences in NICU admissions and Apgar
scores. There was no difference in vaginal deliveries
within 24 hours [51].
Unfavorable cervix subgroup
In 1 trial with 100 primiparous participants, there was
no difference in caesarean section among women receiv-
ing IV prostaglandins and women receiving IV oxytocin
[51].
Summary: Intravenous prostaglandins have no advan-
tages and increase maternal side effects compared to
other methods of induction. This method of induction of
labour has not entered into general use and is of histori-
cal interest only.
Oral prostaglandins (excluding misoprostol)
Our search identified one Cochrane systematic review
comparing oral PGE2 with other methods of induction
of labour [52]. This review included 19 studies with
2588 women. Included studies compared oral PGE2
with placebo, cervical or vaginal PGE2, or oral or IV
oxytocin, with or without amniotomy. There was no dif-
ference in the number of participants who achieved
vaginal delivery within 24 hours between women receiv-
ing oral PGE2 and controls who received IV oxytocin.
Oral PGE2 was associated with fewer caesarean deliv-
eries than placebo (3 studies, 195 women, 14/105 versus
20/90; RR 0.54, 95% CI 0.29 to 0.98; NNT = 10). There
was no difference in caesarean delivery between subjects
induced with oral PGE2 and other methods of induc-
tion. Oral PGE2 was associated with increased vomiting
compared to IV oxytocin (3 studies, 305 women, 25/150
versus 4/155; RR 5.56, 95% CI 2.15 to14.38; NNH = 9).
More women allocated to oral PGE2 experienced diar-
rhea (2 studies, 236 women, 6/114 versus 0/122; RR
8.13, 95% CI 1.03 to 63.93; NNH = not estimable) com-
pared with IV oxytocin. There were no significant differ-
ences in other maternal or fetal outcomes in any of the
other comparison groups [52].
Unfavorable cervix subgroup
Among women with unfavorable cervices, oral PGE2
was associated with fewer caesarean deliveries than pla-
cebo (3 studies, 195 women, 14/105 versus 20/90; RR
0.54, 95% CI 0.29 to 0.98; NNT = 10). There was no dif-
ference between caesarean deliveries among women
receiving oral prostaglandins and those receiving vaginal
prostaglandins (2 trials, 63 women), cervical prostaglan-
dins (1 trial, 50 participants), or oxytocin (3 trials, 171
women) [52].
Summary: Oral prostaglandins are associated with
increased maternal vomiting and diarrhea compared
with IV oxytocin.
Mifepristone
Our search uncovered one systematic review of mife-
pristone for induction of labour combining 10 trials
including 1108 women [53]. The authors found that
mifepristone was superior to placebo in achieving a
favourable cervical score or initiating labour within 48
hours (4 studies, 293 women, 75/152 versus 27/171; RR
2.41, 95% CI 1.70 to3.42, NNT = 4). Compared to pla-
cebo, mifepristone reduced the risk for caesarean section
(9 trials, 1043 women, 163/661 versus 113/382; RR 0.74,
95% CI 0.60 to 0.92; NNT = 14), but increased the risk
for instrumental vaginal delivery (7 trials, 814 women,
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139/540 versus 47/274; RR 1.43, 95% CI 1.04 to1.96;
NNH = 14). Compared to placebo, mifepristone
increased the likelihood of FHR abnormalities (5 trials,
721 women, 101/493 versus 35/228; RR 1.60, 95% CI
1.12 to 2.29; NNH = 11), but did not adversely affect
neonatal outcomes [53].
The reviewers included one study comparing mifepris-
tone to oxytocin for induction of labor among women
with PROM at term. That study found that compared
with oxytocin, mifepristone decreased the proportion of
women who were delivered vaginally within 24 hours (1
study, 65 participants, 17/33 versus 25/32, RR 0.66, 95%
CI 0.45 to 0.96, NNH = 3). Mifepristone was associated
with increased FHR tracing abnormalities (9/33 versus
2/32, RR 4.46, 95% CI 1.02 to 18.66, NNH = 4) and neo-
natal ICU admissions (11/33 versus 3/32, RR 3.56, 95%
CI 1.09 to 11.58, NNH = 4) [53].
Unfavorable cervix subgroup
Among women with unfavorable cervices, mifepristone
reduced the likelihood of caesarean section compared
with placebo (8 trials, 919 participants, 153/599 versus
96/320, RR 0.77 95% CI 0.61 to 0.96, NNT = 15) [53].
Summary: The use of mifepristone for labour induction
is currently investigational.
Oestrogens
Our search uncovered one systematic review of oestro-
gens with or without amniotomy for induction of labour
that included seven RCTs and a total of 465 women
[54]. Five studies including 306 subjects compared oes-
trogen with placebo. There were no differences in rates
of caesarean deliveries, operative vaginal deliveries or
uterine hyperstimulation with or without FHR changes
between groups. There were no differences between oes-
trogens and vaginal prostaglandins in caesarean deliv-
eries, uterine hyperstimulation with or without FHR
changes, or epidural analgesia (1 trial, 60 women).
There were no differences between oestrogens and cer-
vical prostaglandins in cesarean deliveries or instrumen-
tal vaginal deliveries (2 trials, 151 women). There was
no difference between oestrogens and cervical prosta-
glandins in serious maternal complications or NICU
admissions in 1 trial with 85 women. There were no dif-
ferences between oestrogens and oxytocin in caesarean
deliveries or operative vaginal deliveries in one trial
including 66 women [54].
Unfavorable cervix subgroup
In three trials including 162 women, there was no differ-
ence in caesarean sections between women receiving
oestrogens and placebo. There was no difference in cae-
sarean deliveries between women receiving oestrogens
and vaginal prostaglandins (1 trial, 60 women), cervical
prostaglandins (one trial, 66 women), extra-amniotic
prostaglandins (one trial, 30 women), or oxytocin (one
trial, 66 women) [54].
Summary: The use of oestrogens for induction of labour
is currently investigational.
Corticosteroids
In a Cochrane review, Kavanagh and colleagues identi-
fied eight studies examining the use of corticosteroids
for labour induction [55]. Seven of these did not meet
the authors’ inclusion criteria. The one included trial
had 66 women and evaluated post-term pregnancies
which were randomly assigned to receive two dexa-
methasone injections (12 and 24 hours prior to oxytocin
infusion) or no treatment prior to oxytocin. There were
no differences in caesarean deliveries, uterine hypersti-
mulation with or without FHR changes, Apgar less than
7 at five minutes or maternal fevers [55].
Unfavorable cervix subgroup
There was no information about the efficacy of corticos-
teroids for induction of labor among women with unfa-
vorable cervices [55].
Summary: The use of corticosteroids for induction of
labour is currently investigational.
Relaxin
Our search identified one Cochrane review that com-
bined four studies including 267 women who used
relaxin for induction of labour [56]. Compared with pla-
cebo or no treatment, relaxin reduced the number of
participants with unfavourable cervices after 24 hours (3
studies, 173 women, 21/96 versus 37/75; RR 0.45, 95%
CI 0.28 to 0.72; NNT = 4), but the need for oxytocin
augmentation was not reduced (3 trials, 196 women, 65/
121 versus 53/75; RR 0.83, 95% CI 0.65 to1.06). There
were no differences in the rates of cesarean delivery,
operative vaginal deliveries, or uterine hyperstimulation
without FHR changes. There were insufficient data to
evaluate perinatal death or morbidity [56].
Unfavorable cervix subgroup
In three trials with 207 women, there was no difference
in caesarean deliveries in women allocated to receive
relaxin compared with placebo [56].
Summary: The use of relaxin for induction of labour is
currently investigational.
Hyaluronidase
We identified one Cochrane systematic review that
included one RCT with 168 women [57]. Women were
randomly assigned to undergo intracervical hyaluroni-
dase or placebo injections. Women receiving hyaluroni-
dase injections were significantly less likely to require
cesarean section (15/83 versus 42/85; RR 0.37, 95% CI
0.22 to 0.61; NNT = 4) and were less likely to require
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oxytocin augmentation (8/83 versus 40/85; RR 0.20, 95%
CI 0.10 to 0.41; NNT = 3). Fewer women allocated to
hyaluronidase had a cervix unfavorable/unchanged after
24 hours 50/83 versus 83/85, RR 0.62, 95% CI 0.52 to
0.74, NNT = 3), No adverse effects were reported [57].
Unfavorable cervix subgroup
This included systematic review did not report any sub-
group analyses according to cervical status [57].
Summary: The use of hyaluronidase for induction of
labour is currently investigational.
Isosorbide Mononitrate
Our search identified two randomised controlled trials
with a total of 502 participants comparing isosorbide
mononitrate, a nitric oxide donor, with placebo [58] or
PGE2 [59]. The Habib trial compared isosorbide mono-
nitite tablets with a pyridoxine placebo; after receiving
the trial medication, subjects received PGE2 or oxytocin
according to hospital protocol. Compared with placebo,
isosorbide mononitrate reduced the number of women
who required treatment with PGE2 (32 of 51 versus 46
of 51, P = 0.002). However, isosorbide mononitrate
increased the need for oxytocin augmentation (48 of 51
versus 27 of 51, P = 0.0001). More women who received
placebo experienced uterine tachysystole. Compared
with placebo, isosorbide mononitrate significantly shor-
tened the admission to delivery interval (102 women,
13.45 +/- 6.63 versus 20.12 +/- 8.19; P = 0.0001). There
was no difference in vaginal deliveries or cesarean sec-
tions between the groups [58]. The PRIM study com-
pared isosorbide mononitrate to PGE2 [59]. Compared
with PGE2, isosorbide mononitrite significantly length-
ened the time from treatment to delivery (398 partici-
pants, 39,7 ± 12.0 hours versus 26.9 +.12.5 hours, mean
difference -12.8 hours, 95% CI -15.2 hours– -10.4 hours,
P < 0.0001). There was no difference in spontaneous
vaginal deliveries, operative vaginal deliveries, or cesar-
ean sections [59].
Unfavorable cervix subgroup
Both the Osman and Habib trials required the qualifying
women to have cervices unfavorable for induction
[58,59].
Summary: The use of isosorbide mononitrite for induc-
tion of labour is currently investigational.
Discussion
Our best-evidence review of the literature suggests that
many commonly-recommended methods for induction
of labour have important trade-offs between benefits
and harms. Compared with placebo, use of vaginal and
cervical prostaglandin E2 was consistently associated
with reduced likelihood of failure to deliver vaginally
within 24 hours but increased risk for hyperstimulation
with and without FHR changes. Vaginal misoprostol
reduced failure to achieve vaginal delivery within 24
hours compared with vaginal and cervical PGE2, but
increased uterine contractile abnormalities. Likewise,
vaginal misoprostol reduced caesarean deliveries com-
pared with IV oxytocin, but increased uterine hypersti-
mulation. Mechanical methods for induction of labour
were associated with reduced rates of uterine hypersti-
mulation compared with vaginal PGE2 and vaginal mis-
oprostol, but were also associated with increased risk for
maternal and neonatal infectious complications in the
one included systematic review that compared mechani-
cal methods with all other methods pooled. Intravenous
oxytocin with and without amniotomy did not appear to
have significant benefits compared with vaginal PGE2.
Of the non-pharmacologic methods, membrane
sweeping appeared to have the strongest evidence-base.
It was successful in reducing post-term gestations with-
out increasing clinically-important harms. There is not
enough evidence of benefit/safety to recommend the
other non-pharmacologic methods of breast stimulation
and sexual intercourse.
Our review included evaluation of several investiga-
tional methods of induction of labour, of which hyaluro-
nidase appears the most promising. In one small trial,
hyaluronidase reduced the need for oxytocin augmenta-
tion and for caesarean delivery. These findings need to
be confirmed in large, appropriately-powered rando-
mised controlled trials.
Our review may have been limited by restricting our
search to the English-language literature and by publica-
tion bias. Because we used the Cochrane hierarchy, we
compared each method of labour induction only with
methods above them on the Cochrane hierarchy list.
This may have limited the total number of comparisons
made. Likewise, the included studies contained hetero-
geneous populations of women with both intact and
ruptured membranes and cervices favourable and unfa-
vourable for induction. The large number of methods of
induction considered in our review precluded subgroup
analyses according to membrane status. Likewise, we
were not able to consider variation in pharmacologic
preparation and dosing of the different compounds
under study. In our review of methods of induction of
labor in the setting of unfavorable cervix, we did not
identify a clear best choice for induction of labor in this
setting.
Despite the large amount of evidence that we were
able to bring to bear on several common methods of
labour induction, we also found considerable impreci-
sion surrounding benefits and harms of many of the
included methods. Numbers of included women in most
induction randomized trials were too small to exclude
differences in rare adverse outcomes such as uterine
rupture, amniotic fluid embolism, or perinatal asphyxia.
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Further research is necessary to identify potential risks
and benefits of both commonly-used and investigational
methods of induction of labour.
Conclusion
Clinicians should use the best available evidence to
choose methods of labour induction. Researchers and
funding agencies should prioritize studies that can help
to definitively guide care in these situations. Women
should be given information about what is known and
not known regarding methods of induction in order to
be able to participate fully in making decisions about
induction of labour.
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